Reuters logo
BRIEF-Mallinckrodt says FDA grants orphan drug designation to co's development product for duchenne muscular dystrophy
July 12, 2017 / 9:06 PM / 5 months ago

BRIEF-Mallinckrodt says FDA grants orphan drug designation to co's development product for duchenne muscular dystrophy

July 12 (Reuters) - Mallinckrodt Plc

* FDA grants orphan drug designation to Mallinckrodt development product for potential treatment of duchenne muscular dystrophy

* Mallinckrodt Plc - phase 2 trial should begin later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below